BR112021025476A2 - Proteínas de ligação à il1rap - Google Patents
Proteínas de ligação à il1rapInfo
- Publication number
- BR112021025476A2 BR112021025476A2 BR112021025476A BR112021025476A BR112021025476A2 BR 112021025476 A2 BR112021025476 A2 BR 112021025476A2 BR 112021025476 A BR112021025476 A BR 112021025476A BR 112021025476 A BR112021025476 A BR 112021025476A BR 112021025476 A2 BR112021025476 A2 BR 112021025476A2
- Authority
- BR
- Brazil
- Prior art keywords
- il1rap
- binding proteins
- treatment
- antibodies
- present
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
PROTEÍNAS DE LIGAÇÃO À IL1RAP. A presente invenção refere-se geralmente a anticorpos no tratamento de doença humana e redução de eventos adversos a ela relacionados. Mais especificamente, a presente invenção refere-se ao uso de proteínas de ligação à IL1RAP (proteína acessória do receptor de interleucina-1) (incluindo anticorpos antagonistas anti-IL1RAP) e seu uso como tratamento e prevenção de doença humana.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2019093114 | 2019-06-26 | ||
PCT/IB2020/055887 WO2020261097A1 (en) | 2019-06-26 | 2020-06-22 | Il1rap binding proteins |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112021025476A2 true BR112021025476A2 (pt) | 2022-10-11 |
Family
ID=71738216
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112021025476A BR112021025476A2 (pt) | 2019-06-26 | 2020-06-22 | Proteínas de ligação à il1rap |
Country Status (12)
Country | Link |
---|---|
US (1) | US20230295313A1 (pt) |
EP (1) | EP3990494A1 (pt) |
JP (1) | JP2022539178A (pt) |
KR (1) | KR20220026585A (pt) |
CN (1) | CN114222760A (pt) |
AU (1) | AU2020308053A1 (pt) |
BR (1) | BR112021025476A2 (pt) |
CA (1) | CA3143211A1 (pt) |
IL (1) | IL289145A (pt) |
MA (1) | MA56397A (pt) |
MX (1) | MX2021015651A (pt) |
WO (1) | WO2020261097A1 (pt) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022170008A2 (en) * | 2021-02-05 | 2022-08-11 | Boehringer Ingelheim International Gmbh | Anti-il1rap antibodies |
Family Cites Families (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS57106673A (en) | 1980-12-24 | 1982-07-02 | Chugai Pharmaceut Co Ltd | Dibenzo(b,f)(1,4)oxazepin derivative |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
US5559235A (en) | 1991-10-29 | 1996-09-24 | Glaxo Wellcome Inc. | Water soluble camptothecin derivatives |
WO1993022332A2 (en) | 1992-04-24 | 1993-11-11 | Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
US5342947A (en) | 1992-10-09 | 1994-08-30 | Glaxo Inc. | Preparation of water soluble camptothecin derivatives |
US5681835A (en) | 1994-04-25 | 1997-10-28 | Glaxo Wellcome Inc. | Non-steroidal ligands for the estrogen receptor |
US5491237A (en) | 1994-05-03 | 1996-02-13 | Glaxo Wellcome Inc. | Intermediates in pharmaceutical camptothecin preparation |
GB9424449D0 (en) | 1994-12-02 | 1995-01-18 | Wellcome Found | Antibodies |
GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
US6113918A (en) | 1997-05-08 | 2000-09-05 | Ribi Immunochem Research, Inc. | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
GB9716557D0 (en) | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
RS49779B (sr) | 1998-01-12 | 2008-06-05 | Glaxo Group Limited, | Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze |
US6312700B1 (en) | 1998-02-24 | 2001-11-06 | Andrew D. Weinberg | Method for enhancing an antigen specific immune response with OX-40L |
GB9809839D0 (en) | 1998-05-09 | 1998-07-08 | Glaxo Group Ltd | Antibody |
PT1914244E (pt) | 1999-04-09 | 2013-07-26 | Kyowa Hakko Kirin Co Ltd | Processo para regular a actividade de moléculas funcionais sob o ponto de vista imunológico |
BR122014028365B8 (pt) | 1999-06-25 | 2021-07-06 | Genentech Inc | artigo industrializado compreendendo um primeiro recipiente que compreende uma composição de humab4d5-8 nele contida e um segundo recipiente que compreende uma composição rhumab 2c4 nele contida |
US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
EP1212422B1 (en) | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
ES2305086T3 (es) | 2000-05-19 | 2008-11-01 | Corixa Corporation | Tratamiento profilactico y terapeutico de enfermedades alergicas, autoinmunes e infecciosas con compuestos con base de monosacaridos. |
CN1305872C (zh) | 2000-06-30 | 2007-03-21 | 葛兰素集团有限公司 | 喹唑啉类化合物的制备方法 |
JP4843181B2 (ja) | 2000-08-04 | 2011-12-21 | コリクサ コーポレイション | 免疫エフェクター化合物 |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
US6374470B1 (en) | 2000-10-06 | 2002-04-23 | Milliken & Company | Face plate for spun-like textured yarn |
US6525028B1 (en) | 2002-02-04 | 2003-02-25 | Corixa Corporation | Immunoeffector compounds |
US6911434B2 (en) | 2002-02-04 | 2005-06-28 | Corixa Corporation | Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds |
IL164376A0 (en) | 2002-04-03 | 2005-12-18 | Applied Research Systems | Ox4or binding agents, their preparation and pharmaceutical compositions containing them |
DE60317677T2 (de) | 2002-06-13 | 2008-10-30 | Crucell Holland B.V. | Ox40 (=cd134) rezeptor agonisten und therapeutische verwendung |
EP3287144A1 (en) | 2002-07-03 | 2018-02-28 | ONO Pharmaceutical Co., Ltd. | Immunopotentiating compositions |
US7960522B2 (en) | 2003-01-06 | 2011-06-14 | Corixa Corporation | Certain aminoalkyl glucosaminide phosphate compounds and their use |
CA2970873C (en) | 2005-05-09 | 2022-05-17 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
KR101318611B1 (ko) | 2005-07-22 | 2013-11-13 | 교와 핫꼬 기린 가부시키가이샤 | 유전자 재조합 항체 조성물 |
US7923538B2 (en) | 2005-07-22 | 2011-04-12 | Kyowa Hakko Kirin Co., Ltd | Recombinant antibody composition |
PT2594590E (pt) | 2007-12-14 | 2015-01-14 | Bristol Myers Squibb Co | Moléculas de ligação ao recetor humano ox40 |
EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
AU2010305374A1 (en) * | 2009-10-09 | 2012-05-03 | Sanofi | Polypeptides for binding to the "receptor for advanced glycation endproducts" as well as compositions and methods involving the same |
KR101573109B1 (ko) | 2009-11-24 | 2015-12-01 | 메디뮨 리미티드 | B7―h1에 대한 표적화된 결합 물질 |
MY171312A (en) | 2010-08-23 | 2019-10-08 | Univ Texas | Anti-ox40 antibodies and methods of using the same |
US9403906B2 (en) | 2011-01-19 | 2016-08-02 | Cantargia Ab | Method of treatment of a solid tumor with interleukin-1 accessory protein antibody |
AU2012299421B2 (en) | 2011-08-23 | 2016-02-04 | Board Of Regents, The University Of Texas System | Anti-OX40 antibodies and methods of using the same |
WO2014055897A2 (en) | 2012-10-04 | 2014-04-10 | Dana-Farber Cancer Institute, Inc. | Human monoclonal anti-pd-l1 antibodies and methods of use |
GB201403875D0 (en) * | 2014-03-05 | 2014-04-16 | Cantargia Ab | Novel antibodies and uses thereof |
IL250902B (en) * | 2014-09-16 | 2022-08-01 | Symphogen As | Anti-met antibodies and preparations |
CN108026172B (zh) * | 2015-06-26 | 2022-04-29 | 赛诺菲生物技术公司 | 单克隆抗il-1racp抗体 |
EA201891084A1 (ru) * | 2015-11-02 | 2019-10-31 | Антитела к il1rap, биспецифические антигенсвязывающие молекулы, которые связываются с il1rap и cd3, и их применение | |
WO2018071910A2 (en) * | 2016-10-16 | 2018-04-19 | Cellerant Therapeutics, Inc. | Anti-il1-rap antibodies |
-
2020
- 2020-06-22 CN CN202080057966.2A patent/CN114222760A/zh active Pending
- 2020-06-22 BR BR112021025476A patent/BR112021025476A2/pt unknown
- 2020-06-22 US US17/622,689 patent/US20230295313A1/en active Pending
- 2020-06-22 MA MA056397A patent/MA56397A/fr unknown
- 2020-06-22 KR KR1020227002321A patent/KR20220026585A/ko unknown
- 2020-06-22 AU AU2020308053A patent/AU2020308053A1/en active Pending
- 2020-06-22 MX MX2021015651A patent/MX2021015651A/es unknown
- 2020-06-22 CA CA3143211A patent/CA3143211A1/en active Pending
- 2020-06-22 WO PCT/IB2020/055887 patent/WO2020261097A1/en unknown
- 2020-06-22 EP EP20743805.2A patent/EP3990494A1/en active Pending
- 2020-06-22 JP JP2021577576A patent/JP2022539178A/ja active Pending
-
2021
- 2021-12-19 IL IL289145A patent/IL289145A/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN114222760A (zh) | 2022-03-22 |
WO2020261097A1 (en) | 2020-12-30 |
KR20220026585A (ko) | 2022-03-04 |
MX2021015651A (es) | 2022-06-14 |
MA56397A (fr) | 2022-05-04 |
AU2020308053A1 (en) | 2022-01-20 |
US20230295313A1 (en) | 2023-09-21 |
EP3990494A1 (en) | 2022-05-04 |
IL289145A (en) | 2022-02-01 |
CA3143211A1 (en) | 2020-12-30 |
JP2022539178A (ja) | 2022-09-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1123556T1 (el) | Αντισωμα που δεσμευει τις erbb-2 και erbb-3 | |
CY1122458T1 (el) | Αντισωματα αντι-n3pglu αμυλοειδους βητα πεπτιδιου και χρησεις αυτων | |
CL2017001920A1 (es) | Anticuerpos humanos contra glicoproteína del virus ébola | |
ECSP18005520A (es) | Anticuerpos de factor xi y métodos de uso | |
BR112016020315A2 (pt) | anticorpos de proteína acessória do receptor de interleucina-1 humana (il1rap) e seus usos | |
MX2018009011A (es) | Anticuerpos anti receptor 1 transmembrana de tirosina-proteina cinasa (ror1) y usos de los mismos. | |
MX2015009416A (es) | Anticuerpos humanos de la proteina f del virus respiratorio sincitial y metodos de uso de estos. | |
BR112015003459A2 (pt) | moléculas com atividade de ligação ao antígeno e de ligação ao receptor fc gama polivalente | |
AR092779A1 (es) | Composicon farmaceutica que comprende anticuerpos que se unen a conformeros de proteinas tau | |
MA54615A (fr) | Anticorps monoclonal contre le récepteur alpha de l'interleukine-4 humaine et son utilisation | |
UA109633C2 (uk) | Антитіло людини проти тканинного фактора | |
PE20210186A1 (es) | Anticuerpos anti-sortilina y metodos para su uso | |
CO6612253A2 (es) | Agentas y antagonistas fijadores de notch y metodos para el uso de los mismos | |
CY1111714T1 (el) | Δεσμευτικες πρωτεϊνες αυξητικου παραγοντα ηπατοκυτταρων (hgf). | |
CY1124563T1 (el) | Βελτιωμενα antισωmata δεσμευσης πρωτοϊνιδιων α- βητα | |
CL2023001377A1 (es) | Anticuerpos anti-npr1 y usos de los mismos | |
TN2014000513A1 (en) | Dual receptor antagonistic antigen-binding proteins and uses thereof | |
MX2021004779A (es) | Anticuerpos cd47 novedosos y metodos para usarlos. | |
EA201992278A1 (ru) | Способы и композиции для снижения иммуногенности | |
DE602006019977D1 (de) | Therapie mit anti-cd4-antikörpern und bestrahlung | |
PH12019501319A1 (en) | Gremlin-1 crystal structure and inhibitory antibody | |
EA202092085A1 (ru) | ТЕРАПЕВТИЧЕСКИЕ АНТИТЕЛА ПРОТИВ sPLA2-GIB И ИХ ПРИМЕНЕНИЕ | |
BR112021014074A2 (pt) | Proteínas de ligação ao antígeno anti-receptor il2 gama | |
BR112022003956A2 (pt) | Anticorpos anti-cd73 | |
BR112021025476A2 (pt) | Proteínas de ligação à il1rap |